Tomoyuki Yoshikawa

Publication Activity (10 Years)

Years Active: 2017-2018
Publications (10 Years): 5

Top Topics

Combination Therapy

Endometrial Cancer

Endoplasmic Reticulum Stress

Top Venues

Journal of gynecologic oncology

Cancer chemotherapy and pharmacology

Medical oncology (Northwood, London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matuura, Kento Kato, Takahiro Sakamoto, Mika Kuwahara, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Kenichi Furuya
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer chemotherapy and pharmacology 81 (5) (2018)
Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroaki Soyama, Tomoyuki Yoshikawa, Hitoshi Tsuda, Kenichi Furuya
Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis. Journal of gynecologic oncology 29 (2) (2017)
Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroaki Soyama, Tomoyuki Yoshikawa, Hitoshi Tsuda, Kenichi Furuya
Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. Journal of gynecologic oncology 28 (3) (2017)
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review. Cancer chemotherapy and pharmacology 81 (1) (2017)
Hiroaki Soyama, Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Mika Kuwahara, Kento Kato, Tomoyuki Yoshikawa, Hideki Iwahashi, Hitoshi Tsuda, Kenichi Furuya
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin. Medical oncology (Northwood, London, England) 34 (12) (2017)